Business
Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board
Nationally Recognized Expert in Dry Eye Disease, Allergic Conjunctivitis, and Other Ocular Surface Diseases LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":"\nNationally Recognized Expert in Dry Eye Disease, Allergic Conjunctivitis, and Other Ocular Surface Diseases\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the appointment of Paul Karpecki, O.D., FAAO, to the company’s Anterior Segment Scientific Advisory Board (SAB).\n\n\nDr. Karpecki is Clinical Director, Corneal Services and Advanced Ocular Surface Disease at Kentucky Eye Institute and a clinician for Gaddie Eye Centers. He is an Associate Professor at the Kentucky College of Optometry and the Medical Director for Keplr Vision and the Dry Eye Institutes of Kentucky and Indiana. Dr. Karpecki received a Doctor of Optometry from Indiana University.\n\n\n“Paul is a nationally recognized leader in the field of optometry,” said Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “His more than 20 years of expertise is expected to be extremely valuable as we continue to advance reproxalap and our novel RASP inhibitor platform toward NDA submission in dry eye disease and allergic conjunctivitis.”\n\n\nDr. Karpecki is the Chief Medical Editor for Review of Optometry, and has moderated or chaired the Congressional Hearing on the Impact of Dry Eye Disease, the Tear Film and Ocular Surface Society (TFOS) Symposium, and the Dry Eye Summit. He has served on the International Task Force on Dry Eye and the TFOS DEWS II Diagnostic Methodology sub-committee, and is a TFOS Global Ambassador. Dr. Karpecki has authored more than 20 peer-reviewed publications and more than 300 articles that have appeared in non-peer reviewed journals, as well as seven book chapters. Selected in 2015 by Optometric Management as one of the 20 most influential individuals in Optometry, he has given more than 1,000 invited lectures.\n\n\n“I’m honored to contribute my expertise to help inform and shape Aldeyra’s strategy for reproxalap as well as future drug candidates designed to address ocular surface disease,” Dr. Karpecki said. “Reproxalap represents a novel therapeutic approach that has demonstrated statistically significant and clinically relevant activity in dry eye disease and allergic conjunctivitis. Given reproxalap’s profile and unique ...